Active specific immunization in malignant melanoma

F. G. Gercovich, J. U. Gutterman, G. M. Mavligit, Evan M Hersh

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

The effects of active specific immunization with nonirradiated autologous and irradiated cultured allogeneic melanoma tumor cells (TC) on cell associated immunity was studied in 11 patients with widespread malignant melanoma receiving chemoimmunotherapy. Immunization with 1 x 106-8x107 TC was done in the draining area of a BCG scarification on day 7 of the study. The in vitro lymphocyte blastogenic response (BR) to autologous TC was studied in terms of the stimulation index on day 1, 7, 14 and 21. The stimulation index (SI) was the counts per min (cpm) in the TC stimulated culture minus the cpm among the TC alone divided by the cpm in the unstimulated controls. A positive BR was considered as a SI equal to or greater than 3. Six out of 11 patients had a significant increase in BR lasting 7-14 days after immunization. The pre- to postimmunization changes in the SI of the 6 patients were 2.5 to 7.5; 0.7 to 3.2; 0 to 5.2; 0 to 16; 0.1 to 6.6; and 6.5 to 30.0. Nine out of 11 patients showed a delayed local inflammatory reaction at the immunization site. Five out of 11 patients mounted a cutaneous delayed hypersensitivity reaction to autologous tumor cells at a separate test site following immunization. There were no side effects. Active specific immunization in the drainage of a BCG reaction appears to be safe. Since a positive BR to autologous TC correlates with a good prognosis in patients with solid tumors, studies of the immunotherapeutic efficacy of this approach may be warranted.

Original languageEnglish (US)
Title of host publicationMED.PEDIAT.ONCOL.
Pages277-287
Number of pages11
Volume1
Edition3
StatePublished - 1975
Externally publishedYes

Fingerprint

Melanoma
Vaccination
Immunization
Neoplasms
Mycobacterium bovis
Delayed Hypersensitivity
Drainage
Immunity
Cell Culture Techniques
Lymphocytes
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gercovich, F. G., Gutterman, J. U., Mavligit, G. M., & Hersh, E. M. (1975). Active specific immunization in malignant melanoma. In MED.PEDIAT.ONCOL. (3 ed., Vol. 1, pp. 277-287)

Active specific immunization in malignant melanoma. / Gercovich, F. G.; Gutterman, J. U.; Mavligit, G. M.; Hersh, Evan M.

MED.PEDIAT.ONCOL.. Vol. 1 3. ed. 1975. p. 277-287.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gercovich, FG, Gutterman, JU, Mavligit, GM & Hersh, EM 1975, Active specific immunization in malignant melanoma. in MED.PEDIAT.ONCOL.. 3 edn, vol. 1, pp. 277-287.
Gercovich FG, Gutterman JU, Mavligit GM, Hersh EM. Active specific immunization in malignant melanoma. In MED.PEDIAT.ONCOL.. 3 ed. Vol. 1. 1975. p. 277-287
Gercovich, F. G. ; Gutterman, J. U. ; Mavligit, G. M. ; Hersh, Evan M. / Active specific immunization in malignant melanoma. MED.PEDIAT.ONCOL.. Vol. 1 3. ed. 1975. pp. 277-287
@inbook{d68f86ed8a5543ed8458256b92c97263,
title = "Active specific immunization in malignant melanoma",
abstract = "The effects of active specific immunization with nonirradiated autologous and irradiated cultured allogeneic melanoma tumor cells (TC) on cell associated immunity was studied in 11 patients with widespread malignant melanoma receiving chemoimmunotherapy. Immunization with 1 x 106-8x107 TC was done in the draining area of a BCG scarification on day 7 of the study. The in vitro lymphocyte blastogenic response (BR) to autologous TC was studied in terms of the stimulation index on day 1, 7, 14 and 21. The stimulation index (SI) was the counts per min (cpm) in the TC stimulated culture minus the cpm among the TC alone divided by the cpm in the unstimulated controls. A positive BR was considered as a SI equal to or greater than 3. Six out of 11 patients had a significant increase in BR lasting 7-14 days after immunization. The pre- to postimmunization changes in the SI of the 6 patients were 2.5 to 7.5; 0.7 to 3.2; 0 to 5.2; 0 to 16; 0.1 to 6.6; and 6.5 to 30.0. Nine out of 11 patients showed a delayed local inflammatory reaction at the immunization site. Five out of 11 patients mounted a cutaneous delayed hypersensitivity reaction to autologous tumor cells at a separate test site following immunization. There were no side effects. Active specific immunization in the drainage of a BCG reaction appears to be safe. Since a positive BR to autologous TC correlates with a good prognosis in patients with solid tumors, studies of the immunotherapeutic efficacy of this approach may be warranted.",
author = "Gercovich, {F. G.} and Gutterman, {J. U.} and Mavligit, {G. M.} and Hersh, {Evan M}",
year = "1975",
language = "English (US)",
volume = "1",
pages = "277--287",
booktitle = "MED.PEDIAT.ONCOL.",
edition = "3",

}

TY - CHAP

T1 - Active specific immunization in malignant melanoma

AU - Gercovich, F. G.

AU - Gutterman, J. U.

AU - Mavligit, G. M.

AU - Hersh, Evan M

PY - 1975

Y1 - 1975

N2 - The effects of active specific immunization with nonirradiated autologous and irradiated cultured allogeneic melanoma tumor cells (TC) on cell associated immunity was studied in 11 patients with widespread malignant melanoma receiving chemoimmunotherapy. Immunization with 1 x 106-8x107 TC was done in the draining area of a BCG scarification on day 7 of the study. The in vitro lymphocyte blastogenic response (BR) to autologous TC was studied in terms of the stimulation index on day 1, 7, 14 and 21. The stimulation index (SI) was the counts per min (cpm) in the TC stimulated culture minus the cpm among the TC alone divided by the cpm in the unstimulated controls. A positive BR was considered as a SI equal to or greater than 3. Six out of 11 patients had a significant increase in BR lasting 7-14 days after immunization. The pre- to postimmunization changes in the SI of the 6 patients were 2.5 to 7.5; 0.7 to 3.2; 0 to 5.2; 0 to 16; 0.1 to 6.6; and 6.5 to 30.0. Nine out of 11 patients showed a delayed local inflammatory reaction at the immunization site. Five out of 11 patients mounted a cutaneous delayed hypersensitivity reaction to autologous tumor cells at a separate test site following immunization. There were no side effects. Active specific immunization in the drainage of a BCG reaction appears to be safe. Since a positive BR to autologous TC correlates with a good prognosis in patients with solid tumors, studies of the immunotherapeutic efficacy of this approach may be warranted.

AB - The effects of active specific immunization with nonirradiated autologous and irradiated cultured allogeneic melanoma tumor cells (TC) on cell associated immunity was studied in 11 patients with widespread malignant melanoma receiving chemoimmunotherapy. Immunization with 1 x 106-8x107 TC was done in the draining area of a BCG scarification on day 7 of the study. The in vitro lymphocyte blastogenic response (BR) to autologous TC was studied in terms of the stimulation index on day 1, 7, 14 and 21. The stimulation index (SI) was the counts per min (cpm) in the TC stimulated culture minus the cpm among the TC alone divided by the cpm in the unstimulated controls. A positive BR was considered as a SI equal to or greater than 3. Six out of 11 patients had a significant increase in BR lasting 7-14 days after immunization. The pre- to postimmunization changes in the SI of the 6 patients were 2.5 to 7.5; 0.7 to 3.2; 0 to 5.2; 0 to 16; 0.1 to 6.6; and 6.5 to 30.0. Nine out of 11 patients showed a delayed local inflammatory reaction at the immunization site. Five out of 11 patients mounted a cutaneous delayed hypersensitivity reaction to autologous tumor cells at a separate test site following immunization. There were no side effects. Active specific immunization in the drainage of a BCG reaction appears to be safe. Since a positive BR to autologous TC correlates with a good prognosis in patients with solid tumors, studies of the immunotherapeutic efficacy of this approach may be warranted.

UR - http://www.scopus.com/inward/record.url?scp=0016754630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016754630&partnerID=8YFLogxK

M3 - Chapter

VL - 1

SP - 277

EP - 287

BT - MED.PEDIAT.ONCOL.

ER -